Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) price closed higher on Tuesday, March 26, jumping 0.76% above its previous close.
A look at the daily price movement shows that the last close reads $0.65. The company’s 5Y monthly beta was ticking 0.21. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.46 and 52-week low of $0.13. The stock added 83.90% on its value in the past month.
Brainstorm Cell Therapeutics, Inc., which has a market valuation of $32.33 million, is expected to release its quarterly earnings report Mar 28, 2024 – Apr 01, 2024. In this case, analysts estimate an annual EPS growth of -6.10% for the year and 32.90% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give BCLI a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as Hold.
The overview shows that BCLI’s price is at present 71.70% off the SMA20 and 82.37% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 79.93, with weekly volatility standing at 35.07%. The indicator jumps to 16.04% when calculated based on the past 30 days. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s beta value is holding at 0.27, while the average true range (ATR) indicator is currently reading 0.07.
An analysis of the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock in terms of its daily trading volume indicates that the 3-month average is 1.45 million. However, this figure increases on the past 10-day timeline to an average of 1.67 million.
Current records show that the company has 48.98M in outstanding shares. The insiders’ percentage holdings are 17.86% of outstanding shares while the percentage share held by institutions stands at 8.09%. The stats also highlight that short interest as of Feb 29, 2024, stood at 1.07 million shares, which puts the short ratio at the time at 1.21. From this we can glean that short interest is 2.18% of company’s current outstanding shares. Notably, we see that shares short in February fall slightly given the previous month’s figure stood at 2.03 million. But the 141.76% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
